Patients first
people always

At Astria Therapeutics, we are devoted to bringing life-changing therapies to patients and families impacted by allergic and immunologic diseases. Astria’s clinical trials are designed with input from patients, caregivers, and physicians around the world to ensure every aspect of our approach is developed and executed with patients’ real-world needs in mind.

We listen deeply and we care intensely, because putting people first is more than just the right thing to do—it’s how we do our best work.

Currently Enrolling Trials

Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

Atopic Dermatitis (AD)

Currently Enrolling Trials

Hereditary Angioedema (HAE)

A Phase 3 placebo-controlled trial to evaluate the safety and efficacy of navenibart (STAR-0215) in preventing attacks in people with type 1 and type 2 HAE.

ALPHA-ORBIT Trial ClinicalTrials.gov

Hereditary Angioedema (HAE)

Coming Soon: ORBIT-EXPANSE

An extension of the Phase 3 ALPHA-ORBIT trial to evaluate the long-term safety and efficacy of navenibart (STAR-0215) in preventing attacks in people with type 1 and type 2 HAE.

Check back for additional information.

Atopic Dermatitis (AD)

A Phase 1a trial to evaluate STAR-0310 in healthy participants.

ClinicalTrials.gov